These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36531956)

  • 1. Characteristics of Adenosine-to-Inosine RNA editing-based subtypes and novel risk score for the prognosis and drug sensitivity in stomach adenocarcinoma.
    Pan J; Gu X; Luo J; Qian X; Gao Q; Li T; Ye L; Li C
    Front Cell Dev Biol; 2022; 10():1073688. PubMed ID: 36531956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and evaluation of an adenosine-to-inosine RNA editing-based prognostic model for survival prediction of bladder cancer patients.
    Tang YC; Yang CS; Liang MX; Zhang Y; Liu Y; Zou SH; Shi SF
    Medicine (Baltimore); 2023 May; 102(19):e33719. PubMed ID: 37171335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of RNA editing profiles in lung adenocarcinoma.
    Shi S; Chen S; Wang M; Guo B; He Y; Chen H
    Front Genet; 2023; 14():1084869. PubMed ID: 36999050
    [No Abstract]   [Full Text] [Related]  

  • 4. An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma.
    Liu Z; Sun L; Peng X; Liu S; Zhu Z; Huang C
    Apoptosis; 2023 Dec; 28(11-12):1564-1583. PubMed ID: 37580435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nomogram based on A-to-I RNA editing predicting overall survival of patients with lung squamous carcinoma.
    Liu L; Liu J; Deng X; Tu L; Zhao Z; Xie C; Yang L
    BMC Cancer; 2022 Jun; 22(1):715. PubMed ID: 35768804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of three immune subtypes characterized by distinct tumor immune microenvironment and therapeutic response in stomach adenocarcinoma.
    Zhu Y; Zhao Y; Cao Z; Chen Z; Pan W
    Gene; 2022 Apr; 818():146177. PubMed ID: 35065254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constructing a novel gene signature derived from oxidative stress specific subtypes for predicting survival in stomach adenocarcinoma.
    Zhou R; Peng N; Li W
    Front Immunol; 2022; 13():964919. PubMed ID: 36059494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPR176 Is a Biomarker for Predicting Prognosis and Immune Infiltration in Stomach Adenocarcinoma.
    Ni L; Chen S; Liu J; Li H; Zhao H; Zheng C; Zhang Y; Huang H; Huang J; Wang B; Lin C
    Mediators Inflamm; 2023; 2023():7123568. PubMed ID: 37124060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of stomach adenocarcinoma based on fatty acid metabolism-related genes frofiling.
    Liu C; Tao Y; Lin H; Lou X; Wu S; Chen L
    Front Mol Biosci; 2022; 9():962435. PubMed ID: 36090054
    [No Abstract]   [Full Text] [Related]  

  • 10. Construction of a disulfidptosis-related glycolysis gene risk model to predict the prognosis and immune infiltration analysis of gastric adenocarcinoma.
    Liao Z; Xie Z
    Clin Transl Oncol; 2024 Sep; 26(9):2309-2322. PubMed ID: 38587603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of a Prognostic Evaluation Model for Stomach Adenocarcinoma on the Basis of Immune-Related lncRNAs.
    Xu C; Chen Z; Pan X; Liu M; Cheng G; Li J; Mei Y
    Appl Biochem Biotechnol; 2022 Dec; 194(12):6255-6269. PubMed ID: 35904674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a novel copper metabolism-related risk model to predict prognosis and tumor microenvironment of patients with stomach adenocarcinoma.
    Sun D; Zhang H; Zhang C
    Front Pharmacol; 2023; 14():1185418. PubMed ID: 37284310
    [No Abstract]   [Full Text] [Related]  

  • 13. Establishment of the molecular subtypes and a risk model for stomach adenocarcinoma based on genes related to reactive oxygen species.
    Li G; Ping M; Zhang W; Wang Y; Zhang Z; Su Z
    Heliyon; 2024 Mar; 10(5):e27079. PubMed ID: 38463816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of a Four Adenosine-to-Inosine RNA Editing Site-Relevant Prognostic Signature for Assessing Survival in Breast Cancer Patients.
    Wan J; Chen S; Zhang A; Liu Y; Zhang Y; Li Q; Yu Z; Wan Y; Yang L; Wang Q
    Front Oncol; 2022; 12():861439. PubMed ID: 35494026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of
    Zhu M; Cui H; Zhang L; Zhao K; Jia X; Jin H
    Transl Cancer Res; 2022 Jan; 11(1):193-205. PubMed ID: 35261896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of mitochondrial respiratory chain signature for predicting prognosis and immunotherapy response in stomach adenocarcinoma.
    Yang J; Jin F; Li H; Shen Y; Shi W; Wang L; Zhong L; Wu G; Wu Q; Li Y
    Cancer Cell Int; 2023 Apr; 23(1):69. PubMed ID: 37062830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of nucleotide metabolism and neuroendocrine regulation-associated modification patterns in stomach adenocarcinoma with auxiliary prognostic assessment and immunotherapy response prediction.
    Zhang Y; Zeng L; Lin D; Chang G; Zeng Y; Xia Y
    Front Endocrinol (Lausanne); 2022; 13():1076521. PubMed ID: 36726460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunobiological signatures and the emerging role of SPP1 in predicting tumor heterogeneity, malignancy, and clinical outcomes in stomach adenocarcinoma.
    Wu Y; Ren L; Tang Y; Zhu Z; Liu S; Jiang Y; Zhang S; Zhuang X; Chen Y
    Aging (Albany NY); 2023 Oct; 15(20):11588-11610. PubMed ID: 37889539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
    Han C; Zhang C; Wang H; Li K; Zhao L
    BMC Cancer; 2021 Dec; 21(1):1312. PubMed ID: 34876056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.